FDA WARNING_LETTER - Antonio Resendes - October 28, 2011

FDA WARNING_LETTER for Antonio Resendes on October 28, 2011. Product: Drugs. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA WARNING_LETTER for Antonio Resendes on October 28, 2011. Product: Drugs. Access full analysis and detailed observations.

Violation Codes

21 U.S.C. 360b(a)

21 CFR 530.3(a)

21 U.S.C. 360b

21 U.S.C. 342(a)(4)

21 U.S.C. 360b(a)(5)

21 CFR 530.11(c)

21 U.S.C. 351(a)(5)

21 CFR 530.11(a)

21 U.S.C. 342(a)(2)(C)(ii)

21 CFR 530

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Antonio Resendes

Inspection Date

October 28, 2011

Product Type

Drugs

Office

New England District Office

People

Mutahar S. Shamsi (District Director)

ID: 0327d695-cf54-443c-9be6-9f090a694b78

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox